Cart
sales@molnova.com
Parcetasal
CAS No. 87549-36-8
Parcetasal( MR-897 )
Catalog No. M26358 CAS No. 87549-36-8
Parcetasal is a non-steroidal anti-inflammatory agent that can be used in pain relief studies.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 177 | Get Quote |
|
| 10MG | 303 | Get Quote |
|
| 25MG | 515 | Get Quote |
|
| 50MG | 736 | Get Quote |
|
| 100MG | 1017 | Get Quote |
|
| 500MG | 2052 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameParcetasal
-
NoteResearch use only, not for human use.
-
Brief DescriptionParcetasal is a non-steroidal anti-inflammatory agent that can be used in pain relief studies.
-
DescriptionParcetasal is a non-steroidal anti-inflammatory agent that can be used in pain relief studies.
-
In Vitro——
-
In Vivo——
-
SynonymsMR-897
-
PathwayOthers
-
TargetOther Targets
-
RecptorS1P1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number87549-36-8
-
Formula Weight313.309
-
Molecular FormulaC17H15NO5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (398.98 mM)
-
SMILESCC(=O)Nc1ccc(OC2(C)OC(=O)c3ccccc3O2)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Nakamura T, Asano M, Sekiguchi Y, et al.Synthesis and evaluation of CS-2100, a potent, orally active and S1P(3)- sparing S1P(1) agonist. Eur J Med Chem. 2012 May;51:92-8.
molnova catalog
related products
-
6-Aldehydoisoophiopo...
6-Aldehydoisoophiopogonanone A is a natural product from Ophiopogon japonicus.
-
MSC 2032964A
MSC 2032964A is a potent selective ASK1 inhibitor (IC50 = 93 nM) that is oral bioavailable and brain permeable. It inhibited neuroinflammation in mouse EAE models and blocked LPS-induced phosphorylation of ASK1 and p38 in cultured mouse astrocytes.
-
Bepranemab
Bepranemab (UCB 0107), a humanized full-length IgG4 monoclonal antibody, targets the central tau epitope (amino acids 235-250) and is utilized in Alzheimer’s disease (AD) research .
